New cancer drug MBS8(1V270) enters first human trials

NCT ID NCT04855435

Recruiting now Disease control Sponsor: MonTa Biosciences ApS Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Aug 11, 2026 · Updated 3 times

Summary

This early-stage trial is testing an experimental drug called MBS8(1V270), given alone or with the immunotherapy pembrolizumab, in people with advanced solid tumors that have not responded to standard treatments. The main goals are to check safety and find the right dose. About 106 participants will be enrolled, and the study is currently recruiting.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: MBS8(1V270) (an experimental drug) and pembrolizumab (an immunotherapy)
What this could lead to: If it works, this could point toward a new treatment option for advanced solid tumors that have stopped responding to other therapies.
What could go wrong: This is a very early Phase 1 trial with only 106 participants, so it is primarily testing safety, not effectiveness. The drug may cause side effects or fail to shrink tumors.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMOR are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

cutaneous melanoma melanoma metastatic melanoma neoplasm Neoplasm Metastasis uveal melanoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ADVANCED SOLID TUMOR CUTANEOUS MELANOMA UVEAL MELANOMA, METASTATIC

Contacts and locations

Locations

Centro Integral Oncológico Clara Campal (CIOCC)
RECRUITING

Madrid, 28050, Spain
Consorcio Hospital General Universitario de Valencia
RECRUITING

Valencia, Spain
Fundacion Instituto de Investigacion Sanitaria Fundacion Jimenez Diaz (FJD)
RECRUITING

Madrid, 28015, Spain
Herlev and Gentofte Hospital, Center for Cancer Research
RECRUITING

Herlev, DK-2730, Denmark
Institut Catalá de Oncologia - Hospital Duran i Reynals.
RECRUITING

Barcelona, Spain

More trials for these conditions

Other studies related to the condition(s) this trial covers.